Veradigm Ambient Scribe

Two reasons converge on C. First, the module sits inside the Veradigm record system and is bought as part of that relationship rather than selected on its own; the platform carries the value. Second, and more decisive, the model is not Veradigm's. The product agreement states it is powered by AvodahMed, so Veradigm is distributing a third party algorithm rather than owning one. Veradigm names its supplier in its own launch materials and legal terms rather than presenting the intelligence as its own. None of this speaks to the quality of the output.

Diagnosis codes are presented as ICD-10 suggestions for provider review rather than prefilled, and nothing published describes ambient order or prescription drafting. The product agreement makes the client solely responsible for reviewing generated documentation before relying on it.

One capability goes further: real time clinical insight prompts tuned to practice protocols surface care considerations during the encounter, which edges from documentation into decision support and carries a different risk profile from note generation. No confidence threshold, acceptance rate or edit burden figure is published.

The pipeline is described at a high level, speech to text producing a transcript which machine learning and natural language processing convert into a note. Beyond that there is no accuracy figure, no evaluation methodology, no model card and no named models. The OEM structure adds a second layer of opacity: the party accountable for model behavior is AvodahMed, whose own disclosures are separate from Veradigm's, so Veradigm may not be able to answer for the model itself.

The model builder is named. Veradigm's own agreement for the product states that Ambient Scribe is powered by AvodahMed, that Avodah Inc. may assist with implementation, testing and performance, and that use is subject to Avodah's own end user license. The supplier is therefore identifiable, rather than the technology being described as proprietary.

The disclosure stops at that link. No foundation model provider, model class or version below AvodahMed is named, no hosting arrangement is published for the combined product, and no subprocessor list exists for either party. The two companies publish separately and their disclosures do not join up.

Training use makes the chain matter more. The agreement licenses Veradigm to use the client's audio recordings, input data and generated documentation to train, develop and improve the product, and nothing says whether that training happens at Veradigm, at Avodah or both, or whether data is deidentified first.

The contracting counterparty is not the party that can answer questions about the model, so security and model questionnaires sent to Veradigm may need answers from a company the customer has no agreement with.

Named physician testimonials only, including a medical director quoted at launch and a family medicine physician reporting improved documentation quality after six months of use. No study, no controlled comparison, no accuracy benchmark and no third party performance rating is published. Satisfaction anecdotes do not substitute for evidence of benefit.

The B rested on a Veradigm explainer describing capture as producing real time transcripts without generating audio recordings. The product's own agreement says otherwise: Ambient Scribe enables audio recordings and other encounter data to be collected, the client owns the audio recordings and data it inputs, and the client grants Veradigm a license to use, modify and adapt that input data and the generated documentation to train, develop and improve the product. The agreement is the more specific surface, and it governs.

What that leaves is a training license over encounter content with no stated de identification step, no opt out, and no retention period for audio, transcripts or notes. Veradigm is the client's business associate under an existing agreement, so HIPAA's use limits apply, but nothing published says how the training license is squared with them or where the partner company fits.

Business associate status is stated in the product's own agreement. The Veradigm Ambient Scribe Agreement, the click through terms a client accepts to use the module, says Veradigm is the client's business associate and must comply with HIPAA's restrictions and safeguards and with the existing business associate agreement between the parties. Veradigm's privacy policy and security program page sit behind it.

The gap is the chain beneath that status. The agreement acknowledges that the product is powered by AvodahMed and that Avodah Inc. may assist with implementation, testing and performance, and it makes use subject to Avodah's own end user license. It does not say whether Avodah acts as Veradigm's subcontractor under the existing business associate agreement, and no subprocessor list is published. A practice buying a module from its record system supplier, under that supplier's brand, will reasonably assume its existing agreement covers everything; the processing involves a different company.

The agreement also places consent for recording on the client: state laws requiring one or all party consent to record a conversation are the client's responsibility.

The certifications sit on the parent company's security program page. Veradigm states that it engages in certification, accreditation and independent review for its products and services, including SOC 2 Type 2 reports, EHNAC accreditation, EPCS certifications and ISO 9001:2015 reviews, operates a round the clock security operations center, and applies a secure development lifecycle with threat modeling and security testing.

Scope is the open question. The page does not say which products the SOC 2 reports cover, and the ambient module is powered by a separate company, Avodah Inc., which the product agreement says may assist with its implementation, testing and performance. A report covering the record system estate establishes nothing about the partner that handles encounter audio. No trust portal or artifact is published, and the page directs buyers to their client representative for product specific controls.

The product also appears in Veradigm's own application marketplace, whose notice distinguishes self reported readiness from tested certification, so listing there is not evidence that anything was examined.

No clearance claimed and none required for ambient documentation. No United States device pathway attaches to a note the clinician reviews and signs, and the product agreement states that neither Veradigm nor its subcontractors practice medicine and that the product does not replace professional judgment or record review.

The product's scope reaches past narrative documentation. Veradigm's release language describes structured diagnosis code recommendations, automatically identifying and recommending ICD-10 codes, alongside what it calls clinical decision insights support tools and multilingual support, and the product writes discrete structured data such as vital signs into the record.

Two boundaries follow. Diagnosis code recommendation is the reimbursement boundary, since the codes proposed shape what is billed. Decision support is named by the vendor in the feature itself, which is candid, and it identifies the boundary being crossed. The reasoning that keeps decision support outside device regulation depends on a professional being able to review the basis of a recommendation rather than rely on the conclusion, and nothing published says what the insights are grounded in or what the clinician is shown.

The product is branded by the record system vendor and built by a partner. If any component were ever to cross into regulated territory, the manufacturer of record would need establishing between the brand owner and the builder, and that question is cheaper to ask early.

Markets appear to be United States only, and availability is limited to Veradigm's own client base.

One honest scope statement, no governance disclosure. The honest part: Veradigm states that multilingual capture produces ENGLISH documentation output, which tells a buyer plainly that the note will not be in the language the visit was conducted in.

What is absent is everything else: no fairness statement, no subgroup analysis, no accent or dialect performance disclosure, and no acknowledgment that a transcript produced from a non English conversation and rendered into English involves a translation step whose errors are invisible to a reviewer reading only the output.

The product agreement describes a review before commit workflow: encounter documentation is generated for a provider to review and edit before it enters the record, and the client is solely responsible for evaluating it, including by human review, before relying on it. That is a real mechanism for challenging an output.

Nothing stands behind the output, and the agreement says so explicitly. The product is provided as is, with a disclaimer that it will be accurate, complete, error free or free of hallucinations. Veradigm has no obligation to provide fixes or updates during the term and acts only as a liaison to Avodah Inc. on errors. Liability is excluded for lost or corrupted client data and capped at fees paid during a promotion term that the agreement never defines, and a cross reference in the client responsibilities section points to the wrong section. Those are drafting defects in a live instrument, and the undefined cap is the most consequential of them.

The structural point remains. The party the buyer contracts with does not control model behavior, and the party that does has no contract with the buyer beyond its end user license.

Deep inside Veradigm and unavailable outside it, the same shape as the other EHR native scribes here. Notes land directly in the Veradigm EHR, capture runs through a dedicated mobile application, and enhancements reach customers through phased rollout without system upgrades or lengthy implementation cycles, which is a clear advantage of native delivery. Veradigm also runs an app marketplace listing competing scribes, so native does not mean exclusive even inside its own base.

No hosting region, residency option or subprocessor list is published, and the subprocessor question is not hypothetical here. It is named on the product.

The scribe is branded by the record system vendor and powered by a separate company, and the product agreement says Avodah Inc. may assist with implementation, testing and performance. Encounter audio and transcripts are therefore handled by an organization other than the one the buyer contracts with, as the ordinary operating design. What follows is unanswered: where that partner processes, what it retains, for how long, and under what terms with the brand owner.

The integration depth cuts both ways. Running inside the record system is a solid usability gain. Deeper integration also means the partner's software reaches further into the record, and the product writes discrete structured data such as vital signs into the chart rather than only narrative text.

A further layer sits beneath that. The partner's parent operates a language translation division alongside its digital health division, and multilingual support has since been added to the scribe. Whether that capability is delivered by the same entity, a sibling or a further third party changes the subprocessor map again.

A price is published, in the product's own agreement rather than on a pricing page. The Veradigm Ambient Scribe Agreement bills usage at $1 per encounter, payable monthly, with an encounter defined as the moment a user selects Begin Visit and transcription starts. Either party can terminate for convenience on thirty days' notice.

That is enough to size cost before contact. But the product is available only to existing Veradigm record system clients, and the agreement refers to discounted or free product and a promotion term without stating either, so whether the per encounter rate is the standing price is not clear.

Per encounter pricing counts started visits rather than completed notes.

Ambulatory, bounded by the Veradigm installed base, and thinly documented. Note types named are SOAP, clinical and referral. No specialty count, no specialty tuning claim and no list of supported capture languages is published. Documentation output is English regardless of capture language.